Session » Metabolic and Crystal Arthropathies I
-
Abstract Number: 856
Cost-Effectiveness Of Urate Lowering Strategies For The Management Of Gout
-
Abstract Number: 857
Impact of Urate Lowering Therapy On Renal Disease Progression in Patients With Hyperuricemia
-
Abstract Number: 858
Monosodium Urate Crystal Induced Macrophage Inflammation Is Attenuated By Chondroitin Sulfate: Pre-Clinical Model For Gout Prophylaxis?
-
Abstract Number: 859
Knee Effusion: Sensitivity and Specificity Of Ultrasound For The Identification Of Calcium Pyrophosphate Crystals
-
Abstract Number: 861
Many Gout Patients Treated By Rheumatologists Do Not Meet Established Treatment Goals Despite Long-Term Urate Lowering Therapy: Results Of a Gout Patient Encounter Survey
-
Abstract Number: 1173
A Clinically Significant Interaction Between Furosemide and Allopurinol: Potential Implications for Clinical Practice
-
Abstract Number: 1174
Impact Of Bariatric Surgery On Serum Urate Targets in People With Morbid Obesity and Diabetes: A Prospective Longitudinal Study
-
Abstract Number: 1175
ABCG2 May Influence Risk Of Gout Through Extra-Renal Metabolic Pathways: Analysis Of The Effects Of The Q141K Variant On Serum Urate Responses To a Fructose Load
-
Abstract Number: 1176
Pharmacokinetics and Pharmacodynamics Of Pegloticase In Patients With End-Stage Renal Failure Receiving Hemodialysis
-
Abstract Number: 1177
Efficacy and Safety Of Canakinumab Pre-Filled Syringe Versus Triamcinolone Acetonide In Acute Gouty Arthritis Patients
-
Abstract Number: 1178
Effect Of Febuxostat On Serum Urate Levels In Gout Subjects With Hyperuricemia and Moderate-To-Severe Renal Impairment: A Randomized Controlled Trial
-
Abstract Number: 1179
Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Interim Results From a VA Retrospective Cohort Study
-
Abstract Number: 1180
Rising Burden Of Gout and Poor Management Of The Disease In The United Kingdom: A Nationwide Population Study
-
Abstract Number: 1181
The Effect Of Uric Acid Lowering Therapy In Preventing Comorbidity and Acute Attack Of Gout; A Retrospective Study
-
Abstract Number: 1182
The Performance Of a Diagnostic Rule For Acute Gouty Arthritis Without Joint Fluid Analysis: a Validation Study
-
Abstract Number: 1183
The Treatment Of Gout In Relation To The 2012 Uric Acid Target Guidelines In The US Population
-
Abstract Number: 1184
High Mobility Group Box 1 Plays a Role In Gouty Arthritis
-
Abstract Number: 1185
More Than One-Third Of Patients Reach Serum Urate Target and Continue To Report Multiple Flares
-
Abstract Number: 1186
Use Of High-Dose Allopurinol To Reach Serum Uric Acid Targets In Patients With Gout Across Multiple Countries
-
Abstract Number: 1187
A Large-Scale, Multicenter, Prospective, Open-Label, 6-Month Study To Evaluate The Safety Of Allopurinol Monotherapy In Patients With Gout
-
Abstract Number: 1188
An Assessment Of The Response Of Chronic, Occult, Synovial-Based Inflammation Of Gout To Serum Urate Lowering Therapy
-
Abstract Number: 1189
Allopurinol Dose Titration and Efficacy: A Large-Scale, 6-Month, Multicenter, Prospective Study
-
Abstract Number: 1191
Low-Dose Anakinra Is Effective For The Prophylaxis Of Acute Episodes Of Inflammation In Severe Tophaceous Gout
-
Abstract Number: 1192
Pharmacovigilance Update On Pegloticase For Treatment Refractory Gout: United States Clinical Experience Demonstrates The Value Of Serum Uric Acid Monitoring As a Biomarker Of Risk and Efficacy
-
Abstract Number: 1193
Target Tophus Size and Complete Response Rates In Patients Treated With Open-Label Pegloticase For Chronic Gout Refractory To Conventional Therapy
-
Abstract Number: 1194
Enhanced IL-1β and IL-6 Production In Gout Patients Upon Stimulation With Mono Sodium Urate Crystals and Synergizing Agents Compared To Healthy Volunteers
-
Abstract Number: 1195
Sex Differences In Gout Evaluation and Management
-
Abstract Number: 1196
Chronic Renal Injury Does Not Prevent Achievement Of Target Serum Uric Acid In Tophaceous Gout
-
Abstract Number: 1197
Gout Medications and The Risk For Incident Coronary Heart Disease and Stroke: The Framingham Heart Study
-
Abstract Number: 1198
Allopurinol Dose Above Creatinine Clearance Based Dose Is Safe and Effective in Gout – Compliance, Efficacy and Safety At 2 and 3 Years